TY - JOUR
T1 - Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients With Systemic Lupus Erythematosus
AU - the NYU WARCOV Investigators
AU - Fernandez-Ruiz, Ruth
AU - Masson, Mala
AU - Kim, Mimi Y.
AU - Myers, Benjamin
AU - Haberman, Rebecca H.
AU - Castillo, Rochelle
AU - Scher, Jose U.
AU - Guttmann, Allison
AU - Carlucci, Philip M.
AU - Deonaraine, Kristina K.
AU - Golpanian, Michael
AU - Robins, Kimberly
AU - Chang, Miao
AU - Belmont, H. Michael
AU - Buyon, Jill P.
AU - Blazer, Ashira D.
AU - Saxena, Amit
AU - Izmirly, Peter M.
N1 - Publisher Copyright:
© 2020, American College of Rheumatology
PY - 2020/12
Y1 - 2020/12
N2 - Objective: To characterize patients with systemic lupus erythematosus (SLE) affected by coronavirus disease 2019 (COVID-19) and to analyze associations of comorbidities and medications on infection outcomes. Methods: Patients with SLE and reverse transcriptase–polymerase chain reaction–confirmed COVID-19 were identified through an established New York University lupus cohort, query of 2 hospital systems, and referrals from rheumatologists. Data were prospectively collected via a web-based questionnaire and review of medical records. Data on baseline characteristics were obtained for all patients with COVID-19 to analyze risk factors for hospitalization. Data were also collected on asymptomatic patients and those with COVID-19–like symptoms who tested negative or were not tested. Statistical analyses were limited to confirmed COVID-19–positive patients. Results: A total of 226 SLE patients were included: 41 with confirmed COVID-19, 19 who tested negative for COVID-19, 42 with COVID-19–like symptoms who did not get tested, and 124 who remained asymptomatic without testing. Of the SLE patients with confirmed COVID-19, hospitalization was required in 24 (59%) and intensive care unit–level of care in 4, and 4 died. Hospitalized patients tended to be older, nonwhite, Hispanic, have higher body mas index (BMI), history of nephritis, and at least 1 comorbidity. An exploratory (due to limited sample size) logistic regression analysis identified race, presence of at least 1 comorbidity, and BMI as independent predictors of hospitalization. Conclusion: In general, the variables predictive of hospitalization in our SLE patients were similar to those identified in the general population. Further studies are needed to understand additional risk factors for poor COVID-19 outcomes in patients with SLE.
AB - Objective: To characterize patients with systemic lupus erythematosus (SLE) affected by coronavirus disease 2019 (COVID-19) and to analyze associations of comorbidities and medications on infection outcomes. Methods: Patients with SLE and reverse transcriptase–polymerase chain reaction–confirmed COVID-19 were identified through an established New York University lupus cohort, query of 2 hospital systems, and referrals from rheumatologists. Data were prospectively collected via a web-based questionnaire and review of medical records. Data on baseline characteristics were obtained for all patients with COVID-19 to analyze risk factors for hospitalization. Data were also collected on asymptomatic patients and those with COVID-19–like symptoms who tested negative or were not tested. Statistical analyses were limited to confirmed COVID-19–positive patients. Results: A total of 226 SLE patients were included: 41 with confirmed COVID-19, 19 who tested negative for COVID-19, 42 with COVID-19–like symptoms who did not get tested, and 124 who remained asymptomatic without testing. Of the SLE patients with confirmed COVID-19, hospitalization was required in 24 (59%) and intensive care unit–level of care in 4, and 4 died. Hospitalized patients tended to be older, nonwhite, Hispanic, have higher body mas index (BMI), history of nephritis, and at least 1 comorbidity. An exploratory (due to limited sample size) logistic regression analysis identified race, presence of at least 1 comorbidity, and BMI as independent predictors of hospitalization. Conclusion: In general, the variables predictive of hospitalization in our SLE patients were similar to those identified in the general population. Further studies are needed to understand additional risk factors for poor COVID-19 outcomes in patients with SLE.
UR - http://www.scopus.com/inward/record.url?scp=85090978569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090978569&partnerID=8YFLogxK
U2 - 10.1002/art.41450
DO - 10.1002/art.41450
M3 - Article
C2 - 32715660
AN - SCOPUS:85090978569
SN - 2326-5191
VL - 72
SP - 1971
EP - 1980
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
IS - 12
ER -